Recombinant Zoster Vaccine Reduces 3-Year Cardiovascular Risk: Insights From a Multi-Centered Database

Matthew F. Helm, Peter A. Khoury, Haig Pakchanian, Rahul Raiker, Steven Maczuga, Galen T. Foulke

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Background: Herpes zoster increases the risk for stroke and myocardial infarction. Zoster vaccination’s impact on this risk is understudied. This retrospective work sought to determine if prophylactic herpes zoster vaccination may reduce the risk of stroke, myocardial infarction, and/or mortality. Methods: A cohort analysis utilized TriNetX, a national, federated database. In one analysis, patients who received 2 doses of recombinant zoster vaccine (RZV) were compared to adults without RZV. A 1:1 propensity-score match analysis was conducted to adjust for demographics and comorbidities in calculating adjusted Relative Risks (aRR) with 95% confidence intervals. First-time incidences for myocardial infarction, stroke, and mortality were Do Not assessed Copyafter 3 years. A subgroup analysis between RZV and zoster vaccine live (ZVL) was also assessed. Penalties Apply Results: Matched cohorts of 7,657 patients revealed that adults who received 2 doses of RZV were at lower risk of MI (aRR [95% CI])= (0.73 [0.55,0.96]) and mortality (0.7 [0.57,0.88]) while having similar risk for stroke (0.97 [0.75,1.26]). Further subgroup analysis also revealed a reduced risk of 3-year mortality when compared to the ZVL cohort (0.84 [0.74,0.95]). Sample size and comorbidities included in the analysis were limited by using a large database. Conclusions: RZV reduces the 3-year risk for myocardial infarction and mortality.

Original languageEnglish (US)
Pages (from-to)1178-1182
Number of pages5
JournalJournal of Drugs in Dermatology
Issue number12
StatePublished - Dec 2023

All Science Journal Classification (ASJC) codes

  • General Medicine

Cite this